产品
编 号：F752860
分子式：C25H24KN3O6S
分子量：533.64
分子式：C25H24KN3O6S
分子量：533.64
产品类型
规格
价格
是否有货
结构图
CAS No: 2450987-57-0
产品详情
生物活性：
Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model.
体内研究：
Anticancer agent 105 (compound 9cb) (9-9.5 mg/kg，每 3 天一次，持续 22 天；ip) 抑制携带 B16-F10 黑色素瘤的 C57BL/6 小鼠的转移性结节。Animal Model:Pulmonary metastatic melanoma mouse model
Dosage:I: 9-9.5 mg/kg; II: 42-4.6 mg/kg
Administration:IP; once daily every 3rd d for 22 d
Result:Decreased the number of metastatic nodules in mouse.
体外研究：
Anticancer agent 105 (compound 9cb) 显示出对癌细胞的选择性，同时它抑制癌细胞（B16–F10 黑色素瘤）和正常非癌性成纤维细胞 (MEF NF2) 的 IC50 分别为 2.41 μM 和 >100 μM。Anticancer agent 105 (0.5-10 μM; 24 h) 显示出对癌细胞的毒性，并且 (5-20 μM; 48 h) 在 B16-F10 细胞中诱导细胞凋亡和坏死。
Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model.
体内研究：
Anticancer agent 105 (compound 9cb) (9-9.5 mg/kg，每 3 天一次，持续 22 天；ip) 抑制携带 B16-F10 黑色素瘤的 C57BL/6 小鼠的转移性结节。Animal Model:Pulmonary metastatic melanoma mouse model
Dosage:I: 9-9.5 mg/kg; II: 42-4.6 mg/kg
Administration:IP; once daily every 3rd d for 22 d
Result:Decreased the number of metastatic nodules in mouse.
体外研究：
Anticancer agent 105 (compound 9cb) 显示出对癌细胞的选择性，同时它抑制癌细胞（B16–F10 黑色素瘤）和正常非癌性成纤维细胞 (MEF NF2) 的 IC50 分别为 2.41 μM 和 >100 μM。Anticancer agent 105 (0.5-10 μM; 24 h) 显示出对癌细胞的毒性，并且 (5-20 μM; 48 h) 在 B16-F10 细胞中诱导细胞凋亡和坏死。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备